Everolimus
Chemical Name: 42-O-(2-Hydroxyethyl)rapamycin
Purity: ≥98%
Biological Activity
Everolimus is a mTOR inhibitor. Inhibits tumor proliferation in vitro and in vivo. Inhibits VEGF-induced HUVEC proliferation in vitro, but does not affect tumor vascular permeability in mouse models. Immunosuppressant. Activates autophagy.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane et al.
Clin.Cancer Res., 2009;15:1612 -
Chemical modification of rapamycin: the discovery of SDZ RAD.
Sedrani et al.
Transplant Proc., 1998;30:2192 -
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles.
Galluzzi et al.
Nat.Rev.Drug.Discov., 2017;
Product Datasheets
Citation for Everolimus
The citations listed below are publications that use Tocris products. Selected citations for Everolimus include:
1 Citation: Showing 1 - 1
-
A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas.
Authors: Lisa D Et al.
Cancer Discov 2023;13:766-795
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for Everolimus
There are currently no reviews for this product. Be the first to review Everolimus and earn rewards!
Have you used Everolimus?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
